Abbvie Inc. (ABBV) Stock Price & Analysis
Abbvie Inc. (ABBV) rose 0.95% to USD 259.36 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
ABBV last closed at USD 256.92; the session ranged USD 256.77–260.19 on volume of 3,051,954 shares. Market capitalization is $458.24B, with a 52-week range of USD 187.62–261.64 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 259.36 |
|---|---|
| Change | ▲ 0.95% (up) |
| Previous Close | USD 256.92 |
| Open | USD 258.54 |
| Day Range | USD 256.77 – 260.19 |
| 52-Week Range | USD 187.62 – 261.64 |
| Volume | 3,051,954 shares |
| Market Cap | $458.24B |
| Exchange | NYQ |
Technical Analysis (ABBV)
Nexqual's technical model rates ABBV "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.62 (neutral) |
| vs SMA50 | Above (USD 233.3) |
| MACD | 6.41 (positive) |
Analyst Ratings (ABBV)
Wall Street analysts rate ABBV "Buy" based on 28 analysts, with a mean price target of USD 267.79 (range USD 200–328), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 28 |
| Mean Target | USD 267.79 |
| High Target | USD 328 |
| Low Target | USD 200 |
| Buy / Hold / Sell | 24 / 6 / 1 |
Earnings (ABBV)
| Next Earnings Date | 2026-07-31 |
|---|---|
| EPS Estimate | USD 3.64 |
| Revenue Estimate | $16.77B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.65 vs est 2.67 ▼ miss |
| 2025-12-31 | USD 2.71 vs est 2.65 ▲ beat |
| 2025-09-30 | USD 1.86 vs est 1.78 ▲ beat |
| 2025-06-30 | USD 2.97 vs est 2.91 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (ABBV)
| Total Revenue | $62.82B |
|---|---|
| Revenue Growth (YoY) | +12.40% |
| Gross Margin | +72.03% |
| Operating Margin | +32.16% |
| Profit Margin | +5.79% |
| Current Ratio | 0.8 |
| Total Cash | $9.39B |
| Total Debt | $72.91B |
| Free Cash Flow | $20.81B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (ABBV)
Nexqual rates Abbvie Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 32% |
| Balance Sheet | Mixed — $9.39B cash vs $72.9B debt |
| Cash Flow | Strong — FCF $20.8B, 34% margin |
| Efficiency | Mixed — No data |
Ownership (ABBV)
| Insider Ownership | +0.11% |
|---|---|
| Institutional Ownership | +76.91% |
| Shares Outstanding | 1.77B |
| Float | 1.76B |
| Short % of Float | +1.38% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (ABBV)
Abbvie Inc. is led by Robert A. Michael (age 55), CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 01:12 UTC.
| CEO & Chairman of the Board | Robert A. Michael (age 55) |
|---|---|
| Executive VP & CFO | Scott T. Reents (age 57) |
| Executive VP & COO | Azita Saleki-Gerhardt (age 62) |
| Executive VP of Research & Development and Chief Scientific Officer | Roopal B. Thakkar (age 53) |
| Senior Vice President of Investor Relations | Elizabeth Shea |
Major Backers & Investors (ABBV)
Notable institutional backers of Abbvie Inc. include JPMorgan, Morgan Stanley, Capital Group, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 3.21% |
| Morgan Stanley | 2.15% |
| Capital Group | 1.77% |
| Bank of America Corporation | 1.35% |
| Fidelity | 1.28% |
| FMR, LLC | 1.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.51% |
| BlackRock | 9.85% |
| State Street | 5.81% |
| Geode Capital | 2.65% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Abbvie Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
- The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
- In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis.
- Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABT | Abbott Laboratories | USD 103.06 | ▲ 2.48% |
| BMY | Bristol-Myers Squibb Company | USD 62.09 | ▲ 2.19% |
| JNJ | Johnson & Johnson | USD 263.4 | ▲ 3.04% |
| GILD | Gilead Sciences, Inc. | USD 129.31 | ▼ 0.79% |
| MRK | Merck & Company, Inc. | USD 131.07 | ▲ 2.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.